Cavitation Board Backs BrightFlixx Tender as Fair Value, Final Call Pending
CVAT sits 44% above its 52-week low of $0.022 on light trading volume (0.1× avg).
Summary
Cavitation's board filed its Schedule 14D-9 response to BrightFlixx Finance's all-cash tender for all outstanding shares, saying the offer provides fair value and a meaningful premium to recent trading prices. The endorsement is conditional: the board will not issue a final recommendation until the final offer price is announced and the fairness opinion is reviewed. This builds on the October 21 launch of the tender at an initial estimated $0.105 per share and the November 3 filing where the board unanimously recommended shareholders tender, with the estimate then put at $0.0975-$0.10 per share. For a company with zero revenue, a $208,000 quarterly net loss and a going-concern warning, the board's fair-value stance is the main support for the deal getting done. The next hard data points are the final offer price and the fairness opinion, which determine whether the premium holds.
At the time of this announcement, CVAT was trading at $0.03 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $10.1M. The 52-week trading range was $0.02 to $0.11. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.